This is still worthy of a reread on a quiet holida

This is still worthy of a reread on a quiet holiday.  Big Jeff posted this on Nov 17 last year, the day I purchased my first CTIX @ .99.  At that point I was very heavily invested in CLSN and noticed CTIX was gaining ground.  I figured I might make some $ in CTIX during December, then move the money back to CLSN at New Years, before CLSN's expected superior results.  That move to CTIX was one of the the best financial  moves I've ever made due to CTIX runup into the 2's before New Year.  The other good move was only moving 1/2 back to CLSN at New Year.  As my wife frequently points out, the bad move was not keeping it all in CTIX

CTIX Value Per Leo:

What valuation would you put on the company?

Leo Ehrlich: The valuation of any company is a reflection of potential future sales. As such, clinical trials will truly help us define where we stand. There is countless biotechnology companies listed on all the exchanges that do not have a product on the market that carry valuations that far, far exceed ours. The caveat is that many of those biotechs are targeting very specific diseases which, although the market potential can still be large, does not compare with the magnitude of the impact that our drug Kevetrin could have on the cancer industry. Apparently as a result of our potential and target patients, investors have made comparisons to companies such as Pharmassets, Inc. (NASDAQ:VRUS) and Medivation, Inc. (NASDAQ:MDVN) [Interviewers' NOTE: Market caps: Pharmassets $5.1 billion, Medivation $1.4 billion, Cellceutix $40 million] because of the possible impact of their drugs on the Hepatitis C and prostate cancer industries, respectively, even though neither have FDA approval yet. In all fairness to them, both are a couple years ahead of us in development, showing strong clinical data and have cash on their balance sheet. But, in all fairness to us, neither VRUS nor MDVN has ever had a share value as low as ours and our target market is significantly larger. By no means would I draw a comparison today to either, but it certainly does demonstrate the potential upside as to where we could be should clinical trials validate our contentions.